Diabetes Drug Elevates Bladder Cancer Risk, University of Alberta Study

Pioglitazone, a drug commonly prescribed for type 2 diabetes, may also elevate bladder cancer risk, says a new Canadian research. In a bid to link pioglitazone and bladder cancer, researchers conducted a systematic review and analysis of clinical trials and observational studies involving over 2.6 million patients. "We observed an increased risk of bladder cancer associated with the use of thiazolidinediones," writes Jeffrey Johnson from the School of Public Health, University of Alberta and study co-author, the Canadian

Back to news